Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
ILR-H82F9 | Human | Biotinylated Human IL-6 R alpha / CD126 Protein, Fc,Avitag™ | ![]() |
![]() ![]() |
![]() ![]() |
ILR-M82E9 | Mouse | Biotinylated Mouse IL-6 R alpha / CD126 Protein, His,Avitag™ | ![]() |
![]() ![]() |
![]() ![]() |
ILR-H5259 | Human | Human IL-6 R alpha / CD126 Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
CD6-H82E8 | Human | Biotinylated Human IL-6 R alpha / CD126 Protein, Avitag™,His Tag | ![]() |
![]() ![]() |
![]() ![]() |
ILR-H4223 | Human | Human IL-6 R alpha / CD126 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
Loaded Human IL-6 R alpha, Fc Tag (Cat. No. ILR-H5259) on Protein A Biosensor, can bind ActiveMax® Human IL-6, Tag Free(Cat. No. IL6-H4218) with an affinity constant of 35.9 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Satralizumab | RG-6168; SA-237 | Approved | Chugai Pharmaceutical Co Ltd | Enspryng, エンスプリング | EU | Neuromyelitis Optica | Roche Registration Gmbh | 2020-06-29 | Myasthenia Gravis; Neuromyelitis Optica | Details |
Sarilumab | REGN-88; SAR-153191 | Approved | Sanofi, Regeneron Pharmaceuticals Inc | Kevzara | Japan | Arthritis, Rheumatoid | Sanofi | 2017-05-22 | Arthritis, Rheumatoid; Spondylitis, Ankylosing; Coronavirus Disease 2019 (COVID-19); Arthritis, Juvenile; Coronavirus Infections | Details |
Tocilizumab | MRA; rhPM-1; RG-1569; HPM-1; MRA-SC; R-1569; RO-48775533 | Approved | Chugai Pharmaceutical Co Ltd | Actemra/RoActemra, Actemra, RoActemra, 雅美罗 | EU | Coronavirus Disease 2019 (COVID-19) | Roche Registration Gmbh | 2005-04-11 | Arthritis, Juvenile; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Hepatocellular; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Lymphoma; Colorectal Neoplasms; Lymphoma, Follicular; Lupus Erythematosus, Systemic; Multicentric Castleman's Disease (MCD); Takayasu Arteritis; systemic sclerosis-associated interstitial lung disease; Urinary Bladder Neoplasms; Biliary Tract Neoplasms; Carcinoma, Transitional Cell; Lymphoma, Large B-Cell, Diffuse; Spondylitis, Ankylosing; Scleroderma, Systemic; Coronavirus Disease 2019 (COVID-19); Arthritis, Rheumatoid; Polyarticular Juvenile Idiopathic Arthritis; Giant Cell Arteritis; Cytokine Release Syndrome; Lymphoma, B-Cell; Solid tumours; Liver Neoplasms | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Tocilizumab biosimilar (Fresenius kabi) | MSB-11456 | Phase 3 Clinical | Merck Serono | Arthritis, Rheumatoid; Autoimmune Diseases | Details |
Tocilizumab Biosimilar (qyuns) | QX-003-S | Phase 1 Clinical | Jiangsu Quanxin Biomedical Co Ltd | Arthritis, Rheumatoid | Details |
Tocilizumab biosimilar (AryoGen Pharmed) | Phase 3 Clinical | Aryogen Biopharma | Arthritis, Rheumatoid | Details | |
CMAB806 | CMAB-806 | Phase 3 Clinical | Taizhou Maibo Taike Biotechnology Co Ltd | Arthritis, Rheumatoid; Arthritis | Details |
Levilimab | BCD-089 | Phase 3 Clinical | Biocad | Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19) | Details |
Atexakin alfa | SON-080; r-IL-6 | Phase 2 Clinical | Merck Serono, Weizmann Institute Of Science | Peripheral Nervous System Diseases; Diabetic Neuropathies | Details |
Olamkicept | FE-301; TJ-301; CR-5/18; FE-999301 | Phase 2 Clinical | Conaris Research Institute | Inflammatory Bowel Diseases; Colitis, Ulcerative; Crohn Disease | Details |
Vobarilizumab | ALX-0061; ANTI-IL-6R; 20A11-9mer-ALB11; Anti-IL-6R Nanobody | Phase 2 Clinical | Ablynx | Arthritis, Rheumatoid; Lupus Erythematosus, Systemic | Details |
Recombinant humanized anti-IL-6R antibody (Hisun Pharma) | HS-628 | Phase 3 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Arthritis, Rheumatoid; Arthritis | Details |
Recombinant humanized anti-IL-6R monoclonal antibody (Beijing VDJBio) | Phase 2 Clinical | Beijing Vdjbio Co Ltd | Arthritis, Rheumatoid; Multicentric Castleman's Disease (MCD) | Details |
This web search service is supported by Google Inc.